Page last updated: 2024-08-18

pyrroles and Digestive System Neoplasms

pyrroles has been researched along with Digestive System Neoplasms in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boussaha, T; Lepere, C; Rougier, P; Taieb, J	1
Cottle-Delisle, C; Kebebew, E; Marx, S; Meltzer, P; Merkel, R; Neychev, V; Nilubol, N; Pacak, K; Steinberg, SM; Yao, J	1
Chen, CC; Lin, YC; Liu, YL; Shun, CT; Wu, MS; Yang, PM	1

Reviews

1 review(s) available for pyrroles and Digestive System Neoplasms

Article	Year
Digestive neuroendocrine tumors (DNET): the era of targeted therapies. Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:2 Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bevacizumab; Clinical Trials as Topic; Digestive System Neoplasms; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2013

Article

Year

Digestive neuroendocrine tumors (DNET): the era of targeted therapies.

Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:2

Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bevacizumab; Clinical Trials as Topic; Digestive System Neoplasms; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2013

Trials

1 trial(s) available for pyrroles and Digestive System Neoplasms

Article	Year
Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical tria BMJ open, 2015, May-19, Volume: 5, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cytoreduction Surgical Procedures; Digestive System Neoplasms; Disease-Free Survival; Everolimus; Gastrointestinal Neoplasms; Gastrointestinal Tract; Genotype; Humans; Indoles; Mutation; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Prospective Studies; Pyrroles; Research Design; Sunitinib	2015

Article

Year

Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical tria

BMJ open, 2015, May-19, Volume: 5, Issue:5

Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cytoreduction Surgical Procedures; Digestive System Neoplasms; Disease-Free Survival; Everolimus; Gastrointestinal Neoplasms; Gastrointestinal Tract; Genotype; Humans; Indoles; Mutation; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Prospective Studies; Pyrroles; Research Design; Sunitinib

2015

Other Studies

2 other study(ies) available for pyrroles and Digestive System Neoplasms

Article	Year
Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer research, 2010, Oct-01, Volume: 70, Issue:19 Topics: AMP-Activated Protein Kinase Kinases; Animals; Atorvastatin; Autophagy; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Digestive System Neoplasms; Female; HCT116 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrolides; Mice; Mice, Nude; Protein Kinases; Pyrroles; RNA, Small Interfering	2010
Off-label uses of sorafenib and sunitinib. Technology Evaluation Center Assessment Program. Executive summary, 2008, Volume: 22, Issue:11 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Digestive System Neoplasms; Drug Approval; Female; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Humans; Indoles; Male; Melanoma; Neoplasms, Squamous Cell; Product Labeling; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration	2008

Article

Year

Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies.

Cancer research, 2010, Oct-01, Volume: 70, Issue:19

Topics: AMP-Activated Protein Kinase Kinases; Animals; Atorvastatin; Autophagy; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Digestive System Neoplasms; Female; HCT116 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrolides; Mice; Mice, Nude; Protein Kinases; Pyrroles; RNA, Small Interfering

2010

Off-label uses of sorafenib and sunitinib.

Technology Evaluation Center Assessment Program. Executive summary, 2008, Volume: 22, Issue:11

Topics: Adenocarcinoma; Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Digestive System Neoplasms; Drug Approval; Female; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Humans; Indoles; Male; Melanoma; Neoplasms, Squamous Cell; Product Labeling; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration

2008